CD4 and neoplasm: Docetaxel + NHS-IL-12 combination therapy failed to provide tumor control following CD4+ T cell depletion (p = 0.9968; Fig. 6C), with few animals capable of controlling tumor growth (number of animals with less than 50mm3 reduced from 3/7 to 1/5).